CAT Sues Abbott Over Humira Royalties
The lawsuit follows the breakdown of talks between the two companies over royalty payments for Humira, a treatment for rheumatoid arthritis.
CAT claims it is entitled to about 5.5% of Humira's sales under a licensing contract with Abbott. The U.S. drugmaker has made an initial 3% royalty payment and says it is allowed to offset the costs of its work...
To view the full article, register now.